We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sony Invests Millions in Medical Devices and Clinical Pathology

By LabMedica International staff writers
Posted on 18 May 2012
The Israeli business daily Globes (Israel) reported that Sony Corporation (New York, NY, USA) is actively seeking to invest hundreds of millions of dollars in Israeli medical technologies. More...
The consumer electronics company wants to create patient-friendly medical devices and diagnostic kits that will be used in point-of-care settings.

Sony is preparing for a major expansion into the world of medical devices, with a particular interest in medical laboratory testing and diagnostic test kits. Experts regard Sony’s new strategy as a sign that prospects in diagnostic testing remain strong.

This is a major strategy change for Sony. Company officials state that Sony will rely less on consumer electronics as it shifts its focus to healthcare sectors, in an effort to revive earnings

Sony is interested in the attractive business prospects for moving into healthcare. “As populations age, demand for medical devices rises, and we intend to participate in this,” declared Hiroshi Yoshioka, vice president, Sony, Inc., in the Globes article. The Globes story serves to demonstrate how the boundaries between consumer electronics and medical devices are blurring.

Recently, Sony applied for a patent that would use a wristband to monitor the heart rate, vital signs, and blood glucose levels of the wearer. This information would be transmitted to a compatible HDTV where the user could see this data. This would be transmitted to medical personnel if necessary.

The techno Website Engadget posted a news story about how Sony is combining medical device functions with consumer electronics. Pathologists and clinical laboratory managers will find the functions of Sony's patent to be very relevant to their work.

Sony is the latest corporate giant to recognize that it can benefit from the confluence of the fields of biotechnology, medical devices, high tech electronics, information technology, and telecommunications. These various technologies are being combined to create “smart” medical devices, according to BioDFW (Dallas, TX, USA, a life sciences regional alliance.

Related Links:

Globes
Sony Corporation
BioDFW


New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.